References
AHNERT-HILGER, G., DAUZENROTH, M. E., HABERMANN, E., HENSCHEN, A., KRIEGLSTEIN, K., MAULER, F. & WELLER, U. 1990. Chains and fragments of tetanus toxin, and their contribution to toxicity. Journal de Physiologie, 84, 229-236.
ALBRECHT, P., JANSEN, A., LEE, J.-I., MOLL, M., RINGELSTEIN, M., ROSENTHAL, D., BIGALKE, H., et al. 2019. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy.Neurology, 92, e48-e54.
BAKRY, N., KAMATA, Y., SORENSEN, R. & SIMPSON, L. L. 1991. Tetanus toxin and neuronal membranes: the relationship between binding and toxicity. Journal of Pharmacology and Experimental Therapeutics,258, 613-619.
BEISE, J., HAHNEN, J., ANDERSEN-BECKH, B. & DREYER, F. 1994. Pore formation by tetanus toxin, its chain and fragments in neuronal membranes and evaluation of the underlying motifs in the structure of the toxin molecule. Naunyn-Schmiedeberg’s Archives of Pharmacology, 349, 66-73.
BENECKE, R. 2012. Clinical relevance of botulinum toxin immunogenicity.BioDrugs, 26, e1-e9.
BENJAFIELD, A. V., AYAS, N. T., EASTWOOD, P. R., HEINZER, R., IP, M. S., MORRELL, M. J., NUNEZ, C. M., et al. 2019. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. The Lancet Respiratory Medicine,7, 687-698.
BENN, S. C., AY, I., BASTIA, E., CHIAN, R.-J., CELIA, S. A., PEPINSKY, R. B., et al. 2005. Tetanus toxin fragment C fusion facilitates protein delivery to CNS neurons from cerebrospinal fluid in mice.Journal of Neurochemistry, 95, 1118-1131.
BERCSENYI, K., GIRIBALDI, F. & SCHIAVO, G. 2013. The elusive compass of clostridial neurotoxins: Deciding when and where to go? Current Topics in Microbiology and Immunology.
BORELLA-VENTURINI, M., FRASSON, C., PALUAN, F., DE NUZZO, D., DI MASI, G., GIRALDO, M., et al. . 2017. Tetanus vaccination, antibody persistence and decennial booster: a serosurvey of university students and at-risk workers. Epidemiology and Infection, 145,1757-1762.
CALEO, M. & SCHIAVO, G. 2009. Central effects of tetanus and botulinum neurotoxins. Toxicon, 54, 593-599.
CHEN, C., FU, Z., KIM, J.-J. P., BARBIERI, J. T. & BALDWIN, M. R. 2009. Gangliosides as High Affinity Receptors for Tetanus Neurotoxin.The Journal of Biological Chemistry, 284, 26569-26577.
CHEN, S. 2012. Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins,4, 913-939.
CONDUIT, R., SASSE, A., HODGSON, W., TRINDER, J., VEASEY, S. & TUCKER, A. 2007. A neurotoxinological approach to the treatment of obstructive sleep apnoea. Sleep Medicine Reviews, 11, 361-375.
CONNAN, C. & POPOFF, M. R. 2017. Uptake of clostridial neurotoxins into cells and dissemination. Uptake and Trafficking of Protein Toxins. Springer.
DA SILVA ANTUNES, R., PAUL, S., SIDNEY, J., WEISKOPF, D., DAN, J. M., PHILLIPS, E., et al. 2017. Definition of human epitopes recognized in tetanus toxoid and development of an assay strategy to detect ex vivo tetanus CD4+ T cell responses. PloS one,12, e0169086.
DRESSLER, D. 2002. Clinical features of antibody-induced complete secondary failure of botulinum toxin therapy. European neurology,48, 26-29.
DRESSLER, D. 2012. Clinical applications of botulinum toxin.Current Opinion in Microbiology, 15, 325-336.
DRESSLER, D. 2016. Botulinum toxin drugs: brief history and outlook.Journal of Neural Transmission, 123, 277-279.
EISEL, U., JARAUSCH, W., GORETZKI, K., HENSCHEN, A., ENGELS, J., WELLER, U., et al. 1986a. Tetanus Toxin - Primary Structure, Expression in Escherichia-Coli, and Homology with Botulinum Toxins. Embo Journal, 5, 2495-2502.
EISEL, U., JARAUSCH, W., GORETZKI, K., HENSCHEN, A., ENGELS, J., WELLER, U., et al . 1986b. Tetanus toxin: primary structure, expression in E. coli, and homology with botulinum toxins. The EMBO journal,5, 2495-2502.
EISEL, U., REYNOLDS, K., RIDDICK, M., ZIMMER, A. & NIEMANN, H. 1993. Tetanus toxin light chain expression in Sertoli cells of transgenic mice causes alterations of the actin cytoskeleton and disrupts spermatogenesis. The EMBO journal, 12, 3365-3372.
FIGUEIREDO, D. M., HALLEWELL, R. A., CHEN, L. L., FAIRWEATHER, N. F., DOUGAN, G., SAVITT, J. M., et al . 1997. Delivery of recombinant tetanus-superoxide dismutase proteins to central nervous system neurons by retrograde axonal transport. Experimental Neurology,145, 546-554.
FISHMAN, P. S., PARKS, D. A., BOWEN, T. & MATTHEWS, C. C. 2009. Localized tetanus in immunized mice. Neurotoxicology,30, 697-701.
FISHMAN, P. S., SAVITT, J. M. & FARRAND, D. A. 1990. Enhanced CNS uptake of systemically administered proteins through conjugation with tetanus C-fragment. Journal of the Neurological Sciences,98, 311-325.
FRANCIS, J., BASTIA, E., MATTHEWS, C., PARKS, D., SCHWARZSCHILD, M., BROWN, R. & FISHMAN, P. 2004. Tetanus toxin fragment C as a vector to enhance delivery of proteins to the CNS. Brain research,1011, 7-13.
FÜRCH, T., WITTMANN, C., WANG, W., FRANCO-LARA, E., JAHN, D. & DECKWER, W. D. 2007. Effect of different carbon sources on central metabolic fluxes and the recombinant production of a hydrolase from Thermobifida fusca in Bacillus megaterium. Journal of Biotechnology,132, 385-394.
GRAMLICH, P. A., REMINGTON, M. P., AMIN, J., BETENBAUGH, M. J. & FISHMAN, P. S. 2013. Tat-tetanus toxin fragment C: A novel protein delivery vector and its use with photochemical internalization.Journal of Drug Targeting, 21, 662-674.
GRUMELLI, C., VERDERIO, C., POZZI, D., ROSSETTO, O., MONTECUCCO, C. & MATTEOLI, M. 2005. Internalization and mechanism of action of clostridial toxins in neurons. Neurotoxicology, 26,761-767.
HEFTER, H., ROSENTHAL, D., BIGALKE, H. & MOLL, M. 2019. Clinical relevance of neutralizing antibodies in botulinum toxin long-term treated still-responding patients with cervical dystonia.Therapeutic Advances in Neurological Disorders, 12,1756286419892078.
HELTING, T. B. & ZWISLER, O. 1977. Structure of tetanus toxin. I. Breakdown of the toxin molecule and discrimination between polypeptide fragments. Journal of Biological Chemistry, 252,187-193.
HESSE, S., KUTSCHENKO, A., BRYL, B., DEUTSCHLAND, M. & LIEBETANZ, D. 2020. Therapeutic effects of Tetanus neurotoxin in spinal cord injury: a case series on four dogs. Spinal Cord Series and Cases,6, 1-10.
JOHNSON, E. A. 1999. Clostridial toxins as therapeutic agents: benefits of nature’s most toxic proteins. Annu Rev Microbiol, 53,551-75.
KRIEGLSTEIN, K. G., HENSCHEN, A. H., WELLER, U. & HABERMANN, E. 1991. Limited proteolysis of tetanus toxin: relation to activity and identification of cleavage sites. European journal of biochemistry, 202, 41-51.
LALLI, G., BOHNERT, S., DEINHARDT, K., VERASTEGUI, C. & SCHIAVO, G. 2003. The journey of tetanus and botulinum neurotoxins in neurons.Trends in Microbiology, 11, 431-437.
LAURENCE, D. & WEBSTER, R. 1963. Pathologic physiology, pharmacology, and therapeutics of tetanus. Clinical Pharmacology & Therapeutics, 4, 36-72.
LAVINDER, J. J., WINE, Y., GIESECKE, C., IPPOLITO, G. C., HORTON, A. P., LUNGU, O. I., et al . 2014. Identification and characterization of the constituent human serum antibodies elicited by vaccination.Proceedings of the National Academy of Sciences of the United States of America, 111, 2259-2264.
LUKIĆ, I., MARINKOVIĆ, E., FILIPOVIĆ, A., KRNJAJA, O., KOSANOVIĆ, D., INIĆ-KANADA, A. & STOJANOVIĆ, M. 2015. Key protection factors against tetanus: Anti-tetanus toxin antibody affinity and its ability to prevent tetanus toxin – ganglioside interaction. Toxicon, 103,135-144.
MASUYER, G., CONRAD, J. & STENMARK, P. 2017. The structure of the tetanus toxin reveals pH‐mediated domain dynamics. EMBO reports,18, 1306-1317.
MASUYER, G., STANCOMBE, P., CHADDOCK, J. A. & ACHARYA, K. R. 2011. Structures of engineered Clostridium botulinum neurotoxin derivatives.Acta Crystallographica Section F: Structural Biology and Crystallization Communications, 67, 1466-1472.
MAYER, S., LAUMER, M., MACKENSEN, A., ANDREESEN, R. & KRAUSE, S. W. 2002. Analysis of the immune response against tetanus toxoid: enumeration of specific T helper cells by the Elispot assay.Immunobiology, 205, 282-289.
MONHEIT, G. D. & PICKETT, A. 2017. AbobotulinumtoxinA: a 25-year history. Aesthetic surgery journal, 37, S4-S11.
MORENO-IGOA, M., CALVO, A. C., PENAS, C., MANZANO, R., OLIVÁN, S., MUÑOZ, M. J., et al . 2010. Fragment C of tetanus toxin, more than a carrier. Novel perspectives in non-viral ALS gene therapy.Journal of Molecular Medicine, 88, 297-308.
NAUMANN, M., BOO, L. M., ACKERMAN, A. H. & GALLAGHER, C. J. 2013. Immunogenicity of botulinum toxins. Journal of neural transmission, 120, 275-290.
OVESPIAN, S. V., BODEKER, M., O’LEARY, V. B., LAWRENCE, G. W. & OLIVER DOLLY, J. 2015. Internalization and retrograde axonal trafficking of tetanus toxin in motor neurons and trans-synaptic propagation at central synapses exceed those of its C-terminal-binding fragments. Brain Structure and Function, 220, 1825-1838.
PALERMO, A., WEBER, L. K., RENTSCHLER, S., ISSE, A., SEDLMAYR, M., HERBSTER, K., et al . 2017. Identification of a Tetanus Toxin Specific Epitope in Single Amino Acid Resolution. Biotechnology journal, 12, 1700197.
PATIL, S., WILLETT, O., THOMPKINS, T., HERMANN, R., RAMANATHAN, S., CORNETT, E. M., et al . 2016. Botulinum Toxin: Pharmacology and Therapeutic Roles in Pain States. Current Pain and Headache Reports, 20, 1-8.
PIRAZZINI, M., ROSSETTO, O., ELEOPRA, R. & MONTECUCCO, C. 2017. Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.Pharmacological Reviews, 69, 200-235.
PIRAZZINI, M., TEHRAN, D. A., LEKA, O., ZANETTI, G., ROSSETTO, O. & MONTECUCCO, C. 2016. On the translocation of botulinum and tetanus neurotoxins across the membrane of acidic intracellular compartments.Biochimica et Biophysica Acta (BBA) - Biomembranes,1858, 467-474.
POULAIN, B. & POPOFF, M. R. 2019. Why are botulinum neurotoxin-producing bacteria so diverse and botulinum neurotoxins so toxic? Toxins, 11, 34.
QAZI, O., SESARDIC, D., TIERNEY, R., SODERBACK, Z., CRANE, D., BOLGIANO, B. & FAIRWEATHER, N. 2006. Reduction of the ganglioside binding activity of the tetanus toxin HC fragment destroys immunogenicity: implications for development of novel tetanus vaccines. Infect Immun, 74, 4884-91.
RESTANI, L., GIRIBALDI, F., MANICH, M., BERCSENYI, K., MENENDEZ, G., ROSSETTO, O., et al. 2012. Botulinum Neurotoxins A and E Undergo Retrograde Axonal Transport in Primary Motor Neurons. PLoS Pathogens, 8.
ROSSETTO, O., PIRAZZINI, M., BOLOGNESE, P., RIGONI, M. & MONTECUCCO, C. 2011. An update on the mechanism of action of tetanus and botulinum neurotoxins. Acta Chimica Slovenica, 58, 702-707.
SASSE, A., CONDUIT, R., RYAN, D., WOODS, W. & TUCKER, A. P. 2005. A pharmacotherapy for obstructive sleep apnea. Sleep, 28,1015-1016.
SEITHER, R., LORETAN, C., DRIVER, K., MELLERSON, J. L., KNIGHTON, C. L. & BLACK, C. L. 2019. Vaccination Coverage with Selected Vaccines and Exemption Rates Among Children in Kindergarten—United States, 2018–19 School Year. Morbidity and Mortality Weekly Report, 68,905.
SHAPIRA, A. & BENHAR, I. 2010. Toxin-Based Therapeutic Approaches.Toxins, 2, 2519-2583.
STUDIER, F. W. 2005. Protein production by auto-induction in high-density shaking cultures. Protein Expression and Purification, 41, 207-234.
SUTTON, J. M., CHOW-WORN, O., SPAVEN, L., SILMAN, N. J., HALLIS, B. & SHONE, C. C. 2001. Tyrosine-1290 of tetanus neurotoxin plays a key role in its binding to gangliosides and functional binding to neurones.FEBS Letters, 493, 45-49.
TABAN, M. & PERRY, J. D. 2006. Pearls of botox usage.Oculoplastic Surgery, 4, 165-169.
TURTON, K., CHADDOCK, J. A. & ACHARYA, K. R. 2002. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility.Trends in Biochemical Sciences, 27, 552-558.
UMLAND, S. P., NAHREBNE, D. K., RAZAC, S., BEAVIS, A., PENNLINE, K. J., EGAN, R. W. & BILLAH, M. M. 1997. The inhibitory effects of topically active glucocorticoids on IL-4, IL-5, and interferon-γ production by cultured primary CD4+ T cells. Journal of allergy and clinical immunology, 100, 511-519.
WANG, J., MENG, J., LAWRENCE, G. W., ZURAWSKI, T. H., SASSE, A.,et al . 2008. Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics. Journal of Biological Chemistry, 283, 16993-17002.
WANG, J., ZURAWSKI, T. H., MENG, J., LAWRENCE, G. W., AOKI, K. R., WHEELER, L. & DOLLY, J. O. 2012. Novel chimeras of botulinum and tetanus neurotoxins yield insights into their distinct sites of neuroparalysis. FASEB Journal, 26, 5035-5048.
WILSON, P., SLADE, R., CURRIE, B. J., WALTON, S. F., HOLT, D. C., FISCHER, K., et al . 2003. Mechanisms for a novel immune evasion strategy in the scabies mite Sarcoptes scabiei: a multigene family of inactivated serine proteases. Journal of investigative dermatology, 121, 1419-1424.
YOUSEFI, M., TAHMASEBI, F., YOUNESI, V., RAZAVI, A., KHOSHNOODI, J., BAYAT, A. A., et al . 2014. Characterization of neutralizing monoclonal antibodies directed against tetanus toxin fragment C.Journal of Immunotoxicology, 11, 28-34.
YOUSEFI, M., YOUNESI, V., BAYAT, A. A., JADIDI-NIARAGH, F., ABBASI, E., RAZAVI, A., et al . 2016. Comparative human and mouse antibody responses against tetanus toxin at clonal level. Journal of Immunotoxicology, 13, 243-248.